11/27/2013

Purdue Pharma has submitted its abuse-resistant, extended-release formulation Targiniq ER for FDA review. The drug is a combination of oxycodone, the active ingredient of OxyContin, and naloxone, an opioid antagonist intended to reduce the possibility of abuse.

Related Summaries